| Read on web → |
Governor Gavin Newsom closed out his cannabis bill actions with three signatures. On September 27 he signed AB 1965, titled “Cannabis: testing: quality assurance,” and AB 2250, titled “Cannabis: cannabinoids.” On September 30 he signed AB 2532, titled “Cannabis: labels, packaging, and advertising.” The governor’s office lists the bill numbers, titles and dates. Operative dates and section-level detail are still emerging, and we are not reporting provisions we could not trace to the chaptered text. Licensees in California’s regulated market should have counsel read the final bill language before assuming any change to current labeling, testing or cannabinoid rules. Elsewhere this week, four Republican senators asked the Justice Department to investigate Chinese criminal networks in cannabis and intoxicating hemp, a request that cites the December 11 hemp redefinition. Missouri’s health department proposed ownership-rule changes that would allow publicly traded companies to hold cannabis licenses, with comments open until December 2. The SEC sued a Mississippi man over $1.94 million in alleged misuse of investor funds raised for a medical marijuana company. Internationally, it was a quiet week with no primary-sourced developments to report.
This week at a glanceTop story. California’s governor signed AB 1965 (testing quality assurance), AB 2250 (cannabinoids) and AB 2532 (labels, packaging and advertising). The bill titles are confirmed; operative dates and provisions are not yet confirmed from the chaptered text.
Next three.
- Federal: four GOP senators ask the Attorney General to investigate Chinese criminal networks in cannabis and hemp.
- Missouri: DHSS proposes ownership-rule changes, including publicly traded ownership; comments due December 2.
- Mississippi: SEC alleges $1.94 million misappropriated from about 20 investors in a medical marijuana company.
We are opening a set of promotional placements across both The Regulator Brief and cannabisregulations.ai — an array of options built to span every budget, from single-issue newsletter placements to site-wide visibility on the state legality database and blog. Slots are limited, and for now they are offered only to newsletter subscribers and early users.
Fill out the form to learn more →Federal & agency deskWhy it matters: A letter is not a rule, but it shows where federal attention is pointed ahead of the December 11 hemp redefinition. Operators with foreign investors, land purchases or imported inputs such as pesticides and fertilizer should talk to counsel about how those relationships would read under scrutiny. The letter makes allegations; it does not announce any enforcement action.
On September 30, Sens. Tom Cotton, Susan Collins, Pete Ricketts and Ted Budd asked Attorney General Todd Blanche to “investigate the growing role of Chinese transnational criminal organizations in America’s cannabis and intoxicating-hemp markets.” The senators’ release cites a 2025 DEA assessment and April 2026 charges against 29 Chinese nationals in an Oklahoma-based black-market marijuana operation. It also notes that hemp loophole reforms are scheduled to take effect December 11, 2026. We found no Justice Department response.
We found no new action this week on the rescheduling docket or the hemp redefinition timeline.
Statehouse roundupWhy it matters: California licensees face changes to testing, cannabinoid and labeling rules, but the operative dates and requirements are not yet confirmed. Do not rewrite packaging or testing protocols from bill titles alone. Have counsel read the chaptered text and any implementing regulations from the Department of Cannabis Control.
The governor’s legislative update of September 27 lists AB 1965 (Sharp-Collins), “Cannabis: testing: quality assurance,” and AB 2250 (Aguiar-Curry), “Cannabis: cannabinoids,” as signed. The September 30 update lists AB 2532 (Irwin), “Cannabis: labels, packaging, and advertising,” as signed. Effective dates and provisions: details still emerging.
Why it matters: If adopted, the changes would let publicly traded companies hold cannabis licenses and remove preapproval for 50% ownership changes, a significant opening for capital-raising and exit planning. Operators considering outside investment should file comments by December 2 and review with counsel.
On October 1, the Department of Health and Senior Services announced proposed amendments to 19 CSR 100-1.070 and 19 CSR 100-1.100. They would allow publicly traded company ownership in cannabis licenses, let microbusiness licenses transfer to eligible family members, and clarify procedures for recalling untraceable cannabis products. The amendments are set to appear in the November 2 Missouri Register. Comments are due December 2, 2026; the bulletin does not specify a hearing date, and a final version is expected in 2027.
Why it matters: Securities law applies to cannabis capital raises like any other. Operators who raise money from private investors should have counsel review offering disclosures and how investor funds are tracked. These are allegations in a complaint, not findings.
On September 30, the SEC filed SEC v. Thomas J. Moore III in the U.S. District Court for the Southern District of Mississippi (No. 1:26-cv-00286). It alleges Moore misappropriated about $1.94 million of roughly $4.94 million raised from about 20 investors for Mississippi Green Oil, LLC, a medical marijuana company, spending it on personal expenses and failing to pay promised profit distributions. The SEC seeks injunctions, disgorgement and civil penalties.
Why it matters: Anyone selling CBD food products in the EU still lacks an authorized pathway. Treat circulating reports of a first favorable scientific opinion as unconfirmed until EFSA publishes it and the European Commission and member states act.
EFSA has previously paused its CBD novel-food evaluations pending new data. Industry reports of a first opinion are circulating, but we have not located the opinion itself and are not reporting its terms. Details still emerging.
A light week internationally: we found no dated, primary-sourced developments from Germany, Switzerland, Canada or Thailand.
Advertising is now open. Placements across both the newsletter and the website, with promotional options for every budget. Slots are limited — offered to newsletter subscribers and early users first. Fill out the form →
Recreational, medical, THCA, Delta-8, Delta-9, HHC, CBD, and more — cross-referenced across all 50 states plus DC and Puerto Rico. Updated as laws move. The only single source operators can use to scope multi-state compliance before drafting product, packaging, or shipping policy.
Open the state laws database →Need help with anything in this brief?Get a plain-English answer sourced to primary law, in seconds.
Open the assistant →This newsletter is not legal advice — talk to your counsel. Our directory can help you find one.
Browse the directory →One thing to readThe senators’ letter points to the December 11 hemp redefinition. Our explainer on the delay walks through which products are affected and when. Read the summary →
How useful was this week's brief?
Reach the people who write the compliance checks.
The Regulator Brief goes out every Monday to cannabis attorneys, compliance officers, and licensed operators across US states and international jurisdictions. If you want to put your product in front of them, get in touch.
Know someone who'd benefit from this?
Forward it, or use your personal link below. Refer three colleagues and we'll send you our 50-state cannabis legality reference PDF.
Blu Dot surpasses 2,000% ROAS with self-serve CTV ads
Home furniture brand Blu Dot blew up on CTV with help from Roku Ads Manager. Here’s how:
After a test campaign reached 211,000 households and achieved 1,010% ROAS, the brand went all in to promote its annual sales event. It removed age and income constraints to expand reach and shifted budget to custom audiences and retargeting, where intent was strongest.
The results speak for themselves. As Blu Dot increased their investment by 10x, ROAS jumped to 2,308% and more page-view conversions surpassed 50,000.
“For CTV campaigns, Roku has been a top performer,” said Claire Folkestad, Paid Media Strategist, Blu Dot. “Comping to our other platforms, we have seen really strong ROAS… and highly efficient CPMs, lower than any other CTV partner we've worked with.”
Using Roku Ads Manager, the campaign moved from a pilot to a permanent performance engine for the brand.


